ATE338771T1 - Antagonisten des intestinotrophen glp-2 peptides - Google Patents
Antagonisten des intestinotrophen glp-2 peptidesInfo
- Publication number
- ATE338771T1 ATE338771T1 AT97932672T AT97932672T ATE338771T1 AT E338771 T1 ATE338771 T1 AT E338771T1 AT 97932672 T AT97932672 T AT 97932672T AT 97932672 T AT97932672 T AT 97932672T AT E338771 T1 ATE338771 T1 AT E338771T1
- Authority
- AT
- Austria
- Prior art keywords
- peptide
- antagonists
- intestinotroph
- glp
- glucagon
- Prior art date
Links
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 title abstract 3
- 239000005557 antagonist Substances 0.000 title abstract 3
- 102100040918 Pro-glucagon Human genes 0.000 abstract 2
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/605—Glucagons
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/683,890 US5994500A (en) | 1996-07-19 | 1996-07-19 | Antagonists of intestinotrophic GLP-2 peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE338771T1 true ATE338771T1 (de) | 2006-09-15 |
Family
ID=24745881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97932672T ATE338771T1 (de) | 1996-07-19 | 1997-07-18 | Antagonisten des intestinotrophen glp-2 peptides |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US5994500A (cg-RX-API-DMAC7.html) |
| EP (1) | EP0914341B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4026854B2 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE338771T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU739263B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2260291C (cg-RX-API-DMAC7.html) |
| DE (1) | DE69736634T2 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2277676T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO1998003547A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5834428A (en) | 1995-04-14 | 1998-11-10 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| US6184201B1 (en) | 1995-04-14 | 2001-02-06 | Nps Allelix Corp. | Intestinotrophic glucagon-like peptide-2 analogs |
| JP4148994B2 (ja) | 1996-04-12 | 2008-09-10 | １１４９３３６ オンタリオ インコーポレイテッド | グルカゴン様ペプチド―２アナログ |
| US20020025933A1 (en) * | 1996-08-30 | 2002-02-28 | Knudsen Liselotte Bjerre | GLP-2 derivatives |
| CA2236519C (en) * | 1997-05-02 | 2011-09-13 | 1149336 Ontario Inc. | Methods of enhancing functioning of the large intestine |
| SE9802080D0 (sv) * | 1998-06-11 | 1998-06-11 | Hellstroem | Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein |
| PL202367B1 (pl) | 1998-12-07 | 2009-06-30 | Sod Conseils Rech Applic | Związki stanowiące analogi GLP-1, kompozycje zawierające te związki oraz zastosowanie tych związków |
| GB9930882D0 (en) * | 1999-12-30 | 2000-02-23 | Nps Allelix Corp | GLP-2 formulations |
| US7371721B2 (en) * | 2000-09-18 | 2008-05-13 | Sanos Bioscience A/S | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
| US20080249016A1 (en) * | 2000-09-18 | 2008-10-09 | Sanos Bioscience A/S | Use of GLP-2 in a combination treatment for bone-related disorders |
| DK1326630T3 (da) | 2000-09-18 | 2008-09-15 | Sanos Bioscience As | Anvendelse af GLP-2-peptider |
| US20070135345A1 (en) * | 2000-09-18 | 2007-06-14 | Henriksen Dennis B | Use of GLP-2 for the treatment or prevention, of bone-related disorders |
| WO2002066511A2 (en) * | 2001-02-16 | 2002-08-29 | Conjuchem Inc. | Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders |
| WO2004035624A2 (en) * | 2002-10-14 | 2004-04-29 | Novo Nordisk A/S | Glucagon - like peptide - 2 variants |
| EP1592471B1 (en) | 2003-02-04 | 2011-03-23 | Novo Nordisk A/S | Injection device with rotatable dose setting mechanism |
| WO2004085471A2 (en) * | 2003-03-24 | 2004-10-07 | Novo Nordisk A/S | Glp-2 derivatives |
| WO2004103390A2 (en) | 2003-05-15 | 2004-12-02 | Trustees Of Tufts College | Stable analogs of peptide and polypeptide therapeutics |
| EP1711523B1 (en) | 2003-12-16 | 2012-10-10 | Ipsen Pharma | Analogues of glp-1 |
| ES2642214T3 (es) | 2004-01-21 | 2017-11-15 | Novo Nordisk Health Care Ag | Conjugación de péptidos mediante transglutaminasa |
| US7847061B2 (en) | 2004-11-01 | 2010-12-07 | Nps Pharmaceuticals, Inc. | Treatment of short bowel syndrome patients with colon-in-continuity |
| AU2006242998B2 (en) * | 2005-05-04 | 2012-03-22 | Zealand Pharma A/S | Glucagon-like-peptide-2 (GLP-2) analogues |
| WO2007119101A2 (en) * | 2005-12-01 | 2007-10-25 | Nps Allelix Corp. | Assay system for glp-2 receptor ligands |
| WO2008056155A1 (en) | 2006-11-08 | 2008-05-15 | Zealand Pharma A/S | Selective glucagon-like-peptide-2 (glp-2) analogues |
| EP2314616A1 (en) * | 2009-10-23 | 2011-04-27 | Ferring B.V. | Peptidic GLP-2 agonists |
| US9265842B2 (en) | 2010-10-15 | 2016-02-23 | Cornell University | Compositions and methods for treating endocrine, gastrointestinal or autoimmune disorders |
| CN102924589B (zh) * | 2011-08-11 | 2016-08-24 | 中肽生化有限公司 | 胰高血糖素样肽-2(glp-2)的类似物及其制备方法和用途 |
| CN103945861B (zh) | 2011-09-12 | 2018-06-05 | 阿穆尼克斯运营公司 | 胰高血糖素样肽-2组合物及其制备和使用方法 |
| AU2013226090B2 (en) | 2012-02-27 | 2018-03-08 | Amunix Operating Inc. | XTEN conjugate compositions and methods of making same |
| CA2872315A1 (en) | 2012-05-03 | 2013-11-07 | Zealand Pharma A/S | Glucagon-like-peptide-2 (glp-2) analogues |
| KR102502040B1 (ko) | 2016-12-09 | 2023-02-24 | 질랜드 파마 에이/에스 | 아실화 glp-1/glp-2 이중 효능제 |
| WO2018229252A1 (en) | 2017-06-16 | 2018-12-20 | Zealand Pharma A/S | Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues |
| WO2020020904A1 (en) | 2018-07-23 | 2020-01-30 | Zealand Pharma A/S | Therapeutic uses of glp-2 agonists |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2961045B2 (ja) * | 1993-02-24 | 1999-10-12 | 日清製粉株式会社 | 腸管粘膜増強促進剤 |
| US5990077A (en) * | 1995-04-14 | 1999-11-23 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| US5912229A (en) * | 1996-03-01 | 1999-06-15 | Novo Nordisk Als | Use of a pharmaceutical composition comprising an appetite-suppressing peptide |
-
1996
- 1996-07-19 US US08/683,890 patent/US5994500A/en not_active Expired - Fee Related
-
1997
- 1997-07-18 CA CA2260291A patent/CA2260291C/en not_active Expired - Fee Related
- 1997-07-18 EP EP97932672A patent/EP0914341B1/en not_active Expired - Lifetime
- 1997-07-18 WO PCT/CA1997/000521 patent/WO1998003547A1/en not_active Ceased
- 1997-07-18 AT AT97932672T patent/ATE338771T1/de not_active IP Right Cessation
- 1997-07-18 JP JP50640998A patent/JP4026854B2/ja not_active Expired - Fee Related
- 1997-07-18 ES ES97932672T patent/ES2277676T3/es not_active Expired - Lifetime
- 1997-07-18 DE DE69736634T patent/DE69736634T2/de not_active Expired - Lifetime
- 1997-07-18 AU AU36157/97A patent/AU739263B2/en not_active Ceased
-
1999
- 1999-01-19 US US09/233,934 patent/US6489295B1/en not_active Expired - Fee Related
-
2002
- 2002-11-18 US US10/295,820 patent/US20030109449A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE69736634D1 (de) | 2006-10-19 |
| AU739263B2 (en) | 2001-10-11 |
| DE69736634T2 (de) | 2007-10-11 |
| CA2260291C (en) | 2010-09-14 |
| JP2000516579A (ja) | 2000-12-12 |
| AU3615797A (en) | 1998-02-10 |
| JP4026854B2 (ja) | 2007-12-26 |
| US6489295B1 (en) | 2002-12-03 |
| CA2260291A1 (en) | 1998-01-29 |
| WO1998003547A1 (en) | 1998-01-29 |
| US20030109449A1 (en) | 2003-06-12 |
| ES2277676T3 (es) | 2007-07-16 |
| EP0914341B1 (en) | 2006-09-06 |
| US5994500A (en) | 1999-11-30 |
| EP0914341A1 (en) | 1999-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE338771T1 (de) | Antagonisten des intestinotrophen glp-2 peptides | |
| DE69731373D1 (de) | Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen | |
| EP0596024A4 (en) | Lipid conjugates of therapeutic peptides and protease inhibitors. | |
| ATE306931T1 (de) | Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer | |
| ATE177757T1 (de) | Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17 | |
| AU2210899A (en) | Use of a phosphatidylserine/polypeptide conjugate for inducing autoimmunity in the treatment of cancers | |
| ID28003A (id) | Turunan-turunan adamantana | |
| YU46097A (sh) | Nova klasa estara i njihove farmaceutske smeše | |
| IL125981A0 (en) | Improved tissue destruction in cryosurgery | |
| ATE338062T1 (de) | Neuronale, die exozytose hemmende peptide und diese enthaltende kosmetische und pharmazeutische zusammensetzungen | |
| DE69719360D1 (de) | Zusammensetzungen und methoden zur steigerung der darmfunktion | |
| NO971085D0 (no) | Vannopplöselig polymer og peptid modifisert med denne | |
| DK0573551T3 (da) | Serinrige peptidlinkere | |
| CA2253837A1 (en) | Therapeutic uses of bpi protein products for human meningococcemia | |
| ATE396205T1 (de) | Die verwendung von peptiden von il-2 und peptid- derivaten als therapeutische wirkstoffe | |
| RU94046091A (ru) | Полипептидные антагонисты бомбезина, фармацевтическая композиция и способ лечения | |
| DE69420145D1 (de) | Behandlung präkanzeröser läsionen durch muramylpeptide | |
| TR200000455T2 (tr) | Alzheimer hastalığının tedavisinde fankinonun kullanılması. | |
| ATE474589T1 (de) | Angiogene peptide und ihre verwendungen | |
| DK0478631T3 (da) | Målsøgende midler | |
| PT888114E (pt) | Utilizacao de (+)-alfa-(2,3-dimetoxifenil)-1-¬2-(4-fluorofenil)etil|-4-piperidinometanol no tratamento de doencas depressivas e doencas bipolares | |
| NZ500216A (en) | Beta-amyloid peptide-binding proteins and pharmaceutical use | |
| DE68906066D1 (de) | Peptid und dessen salze und antiallergische peptidmittel, welche diese peptide enthalten. | |
| EA200000909A1 (ru) | ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА | |
| BG103905A (en) | New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |